These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28479180)

  • 21. Antimalarial antibody repertoire defined by plasma IG proteomics and single B cell IG sequencing.
    Coelho CH; Nadakal ST; Gonzales Hurtado P; Morrison R; Galson JD; Neal J; Wu Y; King CR; Price V; Miura K; Wong-Madden S; Alamou Doritchamou JY; Narum DL; MacDonald NJ; Snow-Smith M; Vignali M; Taylor JJ; Lefranc MP; Trück J; Long CA; Healy SA; Sagara I; Fried M; Duffy PE
    JCI Insight; 2020 Nov; 5(22):. PubMed ID: 33048842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development and characterization of novel carrier gel core liposomes based transmission blocking malaria vaccine.
    Tiwari S; Goyal AK; Mishra N; Khatri K; Vaidya B; Mehta A; Wu Y; Vyas SP
    J Control Release; 2009 Dec; 140(2):157-65. PubMed ID: 19686788
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1-DiCo malaria vaccine adjuvanted with GLA-SE or Alhydrogel® in European and African adults: A phase 1a/1b, randomized, double-blind multi-centre trial.
    Sirima SB; Durier C; Kara L; Houard S; Gansane A; Loulergue P; Bahuaud M; Benhamouda N; Nebié I; Faber B; Remarque E; Launay O;
    Vaccine; 2017 Oct; 35(45):6218-6227. PubMed ID: 28947345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of a Plasmodium-Specific Carrier Protein To Enhance Production of Recombinant
    Parzych EM; Miura K; Ramanathan A; Long CA; Burns JM
    Infect Immun; 2018 Jan; 86(1):. PubMed ID: 28993460
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A full-length Plasmodium falciparum recombinant circumsporozoite protein expressed by Pseudomonas fluorescens platform as a malaria vaccine candidate.
    Noe AR; Espinosa D; Li X; Coelho-Dos-Reis JG; Funakoshi R; Giardina S; Jin H; Retallack DM; Haverstock R; Allen JR; Vedvick TS; Fox CB; Reed SG; Ayala R; Roberts B; Winram SB; Sacci J; Tsuji M; Zavala F; Gutierrez GM
    PLoS One; 2014; 9(9):e107764. PubMed ID: 25247295
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
    Gozar MM; Muratova O; Keister DB; Kensil CR; Price VL; Kaslow DC
    Exp Parasitol; 2001 Feb; 97(2):61-9. PubMed ID: 11281702
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Functional evaluation of malaria Pfs25 DNA vaccine by in vivo electroporation in olive baboons.
    Kumar R; Nyakundi R; Kariuki T; Ozwara H; Nyamongo O; Mlambo G; Ellefsen B; Hannaman D; Kumar N
    Vaccine; 2013 Jun; 31(31):3140-7. PubMed ID: 23684840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent Functional Immunogenicity of Plasmodium falciparum Transmission-Blocking Antigen (Pfs25) Delivered with Nanoemulsion and Porous Polymeric Nanoparticles.
    Kumar R; Ledet G; Graves R; Datta D; Robinson S; Bansal GP; Mandal T; Kumar N
    Pharm Res; 2015 Dec; 32(12):3827-36. PubMed ID: 26113235
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-lasting and transmission-blocking activity of antibodies to Plasmodium falciparum elicited in mice by protein conjugates of Pfs25.
    Kubler-Kielb J; Majadly F; Wu Y; Narum DL; Guo C; Miller LH; Shiloach J; Robbins JB; Schneerson R
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):293-8. PubMed ID: 17190797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM; Wu CK; Plieskatt J; McAdams DH; Miura K; Ockenhouse C; King CR
    Malar J; 2016 Aug; 15(1):405. PubMed ID: 27515826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A plant-produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice.
    Jones RM; Chichester JA; Mett V; Jaje J; Tottey S; Manceva S; Casta LJ; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Mett V; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    PLoS One; 2013; 8(11):e79538. PubMed ID: 24260245
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nanovaccines for malaria using Plasmodium falciparum antigen Pfs25 attached gold nanoparticles.
    Kumar R; Ray PC; Datta D; Bansal GP; Angov E; Kumar N
    Vaccine; 2015 Sep; 33(39):5064-71. PubMed ID: 26299750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.
    Kapoor N; Vanjak I; Rozzelle J; Berges A; Chan W; Yin G; Tran C; Sato AK; Steiner AR; Pham TP; Birkett AJ; Long CA; Fairman J; Miura K
    Biochemistry; 2018 Feb; 57(5):516-519. PubMed ID: 29323879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Reproducible and Scalable Process for Manufacturing a Pfs48/45 Based
    Singh SK; Plieskatt J; Chourasia BK; Fabra-García A; Garcia-Senosiain A; Singh V; Bengtsson KL; Reimer JM; Sauerwein R; Jore MM; Theisen M
    Front Immunol; 2020; 11():606266. PubMed ID: 33505395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals.
    Barr PJ; Green KM; Gibson HL; Bathurst IC; Quakyi IA; Kaslow DC
    J Exp Med; 1991 Nov; 174(5):1203-8. PubMed ID: 1940798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Improving the malaria transmission-blocking activity of a Plasmodium falciparum 48/45 based vaccine antigen by SpyTag/SpyCatcher mediated virus-like display.
    Singh SK; Thrane S; Janitzek CM; Nielsen MA; Theander TG; Theisen M; Salanti A; Sander AF
    Vaccine; 2017 Jun; 35(30):3726-3732. PubMed ID: 28578824
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.
    Scally SW; McLeod B; Bosch A; Miura K; Liang Q; Carroll S; Reponen S; Nguyen N; Giladi E; Rämisch S; Yusibov V; Bradley A; Lemiale F; Schief WR; Emerling D; Kellam P; King CR; Julien JP
    Nat Commun; 2017 Nov; 8(1):1568. PubMed ID: 29146922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum.
    Kaslow DC; Bathurst IC; Lensen T; Ponnudurai T; Barr PJ; Keister DB
    Infect Immun; 1994 Dec; 62(12):5576-80. PubMed ID: 7960139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.
    Mullen GE; Giersing BK; Ajose-Popoola O; Davis HL; Kothe C; Zhou H; Aebig J; Dobrescu G; Saul A; Long CA
    Vaccine; 2006 Mar; 24(14):2497-505. PubMed ID: 16434128
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.